Downloads
Abstract
Backgroud: Heart failure is a very common clinical syndrome. In clinical practice in Vietnam, research data on the effectiveness and safety of dapagliflozin are limited. This study aims to explore the clinical and paraclinical characteristics of patients with heart failure and reduced left ventricular ejection fraction and evaluate the therapeutic effect of dapagliflozin and cardiovascular events in these patients.
Methods: A cross - sectional description study with follow-up and control was conducted on 216 heart failure patients with reduced left ventricular ejection fraction. These patients were divided into 2 groups: with dapagliflozin treatment (group A) and without dapagliflozin treatment (group B).
Results: The dapagliflozin-treated and non-dapagliflozin-treated groups had a mean age of 69.3 ± 13.6 and 69.6± 15.0 years, respectively; left ventricular ejection fraction was 36.6 ± 8.8 % and 36.4 ± 8.6 %. Compared with before treatment, the dapagliflozin-treated group had an improvement in NYHA class, a decrease in NT-proBNP, and an increase in ejection fraction. The difference was statistically significant (p < 0.05). Adverse events in the dapagliflozin treatment group were < 7% and did not differ from the dapagliflozin treatment group (p > 0.05). The probability of not being readmitted to the hospital due to heart failure in the group using dapagliflozin was statistically higher than in the group not using dapagliflozin.
Conclusion: In Vietnamese people, dapagliflozin was effective in treating heart failure with reduced left ventricular ejection fraction and adverse events were uncommon.
References
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-3287.
Nam HT, Huynh VM. Khuyến cáo về chẩn đoán và điều trị bệnh suy tim cấp và suy tim mạn tính năm 2022. 2022.
Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306-1325.
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-24.
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
AstraZeneca. Forxiga®. 2023; Available from: https:// www.mims.com/vietnam/drug/forxiga/local-product- insert/230717-proposed%20PI-Forxiga-CKD-vn.pdf.
Dương NPN, An TV, Dũng BT. Đặc điểm lâm sàng, cận lâm sàng và giá trị tiên lượng tử vong ngắn hạn của hạ natri máu ở bệnh nhân suy tim mạn phân suất tống máu giảm tại Bệnh viện đa khoa Trung ương Cần Thơ năm 2022-2023. Tạp chí Y dược học Cần Thơ. 2023;61:42-49.
Vân NNT, Anh NĐQ, Sỹ HV, Hoa CN. Khảo sát điều trị suy tim theo khuyến cáo của Hội Tim châu Âu 2016. Tạp chí Y học TP. Hồ Chí Minh. 2021;25(2):35-41.
Nguyễn TĐ, Trần TN, Phạm QT, Đoàn CT, Phan TB, Trần PMĐ, et al. Results of the Heart Failure Management Program at Hue Central Hospital after 1 year of implementation. Tạp chí Tim mạch học Việt Nam. 2023(107E):18-24.
Tsampasian V, Baral R, Chattopadhyay R, Debski M, Joshi SS, Reinhold J, et al. The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis. Cardiol Res Pract. 2021;2021:9927533.
Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180-93.
Docherty KF, Anand IS, Chiang CE, Chopra VK, Desai AS, Kitakaze M, et al. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia. 2022;2(2):139-153.
| Published | 21-06-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 96 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.96.14 | |
| Keywords | Suy tim phân suất tống máu thất trái giảm, dapagliflozin, đái tháo đường, điều trị Heart failure with reduced left ventricular ejection fraction, dapagliflozin, diabetes, treatment |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital